{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:50:36Z","timestamp":1783403436734,"version":"3.54.6"},"reference-count":59,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2025,12,31]]},"DOI":"10.1080\/13696998.2025.2536974","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T08:38:17Z","timestamp":1753432697000},"page":"1226-1240","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Economic evaluation of oral Nirmatrelvir\/ritonavir versus best supportive care in patients at high risk for progression to severe COVID-19 in Germany: a cost-effectiveness analysis"],"prefix":"10.1080","volume":"28","author":[{"given":"Constanze","family":"Schmalhofer","sequence":"first","affiliation":[{"name":"IQVIA Commercial GmbH & Co. OHG","place":["Munich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9741-1193","authenticated-orcid":false,"given":"Eveline","family":"Otte im Kampe","sequence":"additional","affiliation":[{"name":"Pfizer Pharma GmbH","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Eheberg","sequence":"additional","affiliation":[{"name":"IQVIA Commercial GmbH & Co. OHG","place":["Munich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hera","family":"Sandhu","sequence":"additional","affiliation":[{"name":"IQVIA Solutions B.V","place":["Amsterdam, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8898-5657","authenticated-orcid":false,"given":"Martina","family":"Maier","sequence":"additional","affiliation":[{"name":"IQVIA Commercial GmbH & Co. OHG","place":["Munich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Perschke","sequence":"additional","affiliation":[{"name":"IQVIA Commercial GmbH & Co. OHG","place":["Munich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tendai","family":"Mugwagwa","sequence":"additional","affiliation":[{"name":"Pfizer Ltd","place":["Tadworth, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6501-3361","authenticated-orcid":false,"given":"Emma","family":"Fr\u00f6ling","sequence":"additional","affiliation":[{"name":"Pfizer Pharma GmbH","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1486-8795","authenticated-orcid":false,"given":"Agnes","family":"Kisser","sequence":"additional","affiliation":[{"name":"Pfizer Pharma GmbH","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,7,31]]},"reference":[{"key":"e_1_3_5_2_1","unstructured":"Gandhi RT Meyerowitz EA. Coronavirus disease 2019 (COVID-19): epidemiology virology and prevention. Verf\u00fcgbar unter. 2024 [cited 2024 Nov 29]. Available from: https:\/\/www.uptodate.com\/contents\/coronavirus-disease-2019-covid-19-epidemiology-virology-and-prevention#H3392906512."},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-024-01088-w"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2022.27.22.2200396"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-021-11735-3"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.adh2712"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00152-0"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2021.100794"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00633-2"},{"key":"e_1_3_5_10_1","unstructured":"EMA. SmPC: Paxlovid 150\u2009mg + 100\u2009mg film-coated tablets. Verf\u00fcgbar unter. 2024 [cited 2024 Nov 29]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/paxlovid-epar-product-information_en.pdf."},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae551"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2022.105252"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00118-4"},{"key":"e_1_3_5_14_1","volume-title":"Germany: country Health Profile 2023: State of Health in the EU. Paris\/European Observatory on Health Systems and Policies","author":"OECD\/European Observatory on Health Systems and Policies","year":"2023","unstructured":"OECD\/European Observatory on Health Systems and Policies. Germany: country Health Profile 2023: State of Health in the EU. Paris\/European Observatory on Health Systems and Policies. Brussels: OECD Publishing; 2023."},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-024-10838-y"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1174879"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-024-00427-0"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1537018"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.36469\/001c.129067"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12962-025-00604-0"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2023.11.003"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2024.2444836"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2024.10.989"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2023.09.1800"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2024.1432821"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00103-021-03391-0"},{"key":"e_1_3_5_27_1","unstructured":"RKI. Epidemiologisches Bulletin - STIKO: Aktualisierung der COVID-19-Impfempfehlung. Verf\u00fcgbar unter. 2024 [cited 2025 Apr 22]. Available from: https:\/\/www.rki.de\/DE\/Aktuelles\/Publikationen\/Epidemiologisches-Bulletin\/2024\/02_24.pdf?__blob=publicationFile&v=3."},{"key":"e_1_3_5_28_1","unstructured":"Destatis. Gestorbene: Deutschland Jahre Geschlecht Altersjahre: verf\u00fcgbarer Zeitraum: 1956\u20132023. Verf\u00fcgbar unter. 2024 [cited 2024 Nov 29]. Available from: https:\/\/www-genesis.destatis.de\/datenbank\/online\/statistic\/12613\/table\/12613-0003."},{"key":"e_1_3_5_29_1","unstructured":"EMA. ETF statement on the loss of activity of anti-spike protein monoclonal antibodies due to emerging SARS-CoV-2 variants of concern. Verf\u00fcgbar unter. 2022 [cited 2025 Apr 08]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/public-statement\/etf-statement-loss-activity-anti-spike-protein-monoclonal-antibodies-due-emerging-sars-cov-2-variants-concern_en.pdf."},{"key":"e_1_3_5_30_1","unstructured":"G-BA. Justification of the Resolution of the Federal Joint Committee (G-BA) on an Amendment of the Pharmaceuticals Directive: justification of the Resolution of the Federal Joint Committee (G-BA) on an Amendment of the Pharmaceuticals Directive: Annex XII \u2013 Benefit Assessment of Medicinal Products with New Active Ingredients according to Section 35a SGB V Nirmatrelvir\/Ritonavir(COVID-19). Verf\u00fcgbar unter. 2022 [cited 2025 Apr 08]. Available from: https:\/\/www.g-ba.de\/downloads\/40-1465-9107\/2022-12-15_AM-RL-XII_Nirmatrelvir-Ritonavir_D-835_TrG_EN.pdf."},{"key":"e_1_3_5_31_1","unstructured":"IQWiG. General Methods Version 7.0: version 7.0 of 19 September 2023: institute for Quality and Efficiency in Health Care 2023. Verf\u00fcgbar unter. [cited 2024 Nov 29]. Available from: https:\/\/www.iqwig.de\/methoden\/general-methods_version-7-0.pdf."},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2118542"},{"key":"e_1_3_5_33_1","unstructured":"PFIZER PHARMA GmbH. Prescribing information Paxlovid\u00ae 150\u2009mg + 100\u2009mg Filmtabletten. Verf\u00fcgbar unter. 2025 [cited 2025 Jul 07]. Available from: https:\/\/figi.pfizer.de\/sites\/default\/files\/FI-23638.pdf."},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0259370"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0255427"},{"key":"e_1_3_5_36_1","unstructured":"Hildebrandt F Kleppisch M Urban JN et al. Hrsg. Comparing the disease burden of COVID-19 in-patients with and without high risk factors for severe outcomes: a retrospective study using routine hospital data. Presented at 34th ECCMID; April 2024; Barcelona Spain; 2024."},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-022-00896-z"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0263813"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01654-5"},{"key":"e_1_3_5_40_1","unstructured":"Destatis. Pers\u00f6nlicher Inflationsrechner. Verf\u00fcgbar unter. 2024 [cited 2024 Nov 29]. Available from: https:\/\/service.destatis.de\/inflationsrechner\/#graph."},{"key":"e_1_3_5_41_1","unstructured":"Lauer-Fischer GmbH. LAUER-TAXE\u00ae Online 4.0 Stand: 15.11.2024. Verf\u00fcgbar unter. 2024 [cited 2024 Nov 29]. Available from: https:\/\/portal.cgmlauer.cgm.com\/LF\/default.aspx?p=12000."},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2023.2290388"},{"key":"e_1_3_5_43_1","unstructured":"Statista. Durchschnittliche Kosten medizinischer Rehabilitationsleistungen in Deutschland im Jahr 2019 (in Euro). Verf\u00fcgbar unter. 2024 [cited 2024 Nov 29]. Available from: https:\/\/de.statista.com\/statistik\/daten\/studie\/1073278\/umfrage\/durchschnittliche-kosten-medizinischer-reha-leistungen\/#:\u223c:text=Im%20Jahr%202019%20beliefen%20sich k%C3%B6rperlichen%20Erkrankungen%20auf%201.784%20Euro."},{"key":"e_1_3_5_44_1","unstructured":"KBV. Der Einheitliche Bewertungsma\u00dfstab: EBM 2024\/Q4 Stand 20.11.2024. Verf\u00fcgbar unter. 2024 [cited 2024 Nov 29]. Available from: https:\/\/ebm.kbv.de\/."},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1097\/JOM.0000000000003093"},{"key":"e_1_3_5_46_1","unstructured":"Destatis. Erwerbst\u00e4tigenquoten. 1991 bis 2023: Erwerbst\u00e4tigenquoten1 nach Gebietsstand und Geschlecht in der Altersgruppe 15 bis unter 65 Jahren Ergebnisse des Mikrozensus in %. Verf\u00fcgbar unter. 2024 [cited 2024 Nov 29]. Available from: https:\/\/www.destatis.de\/DE\/Themen\/Arbeit\/Arbeitsmarkt\/Erwerbstaetigkeit\/Tabellen\/erwerbstaetigenquoten-gebietsstand-geschlecht-altergruppe-mikrozensus.html."},{"key":"e_1_3_5_47_1","unstructured":"BAuA. Volkswirtschaftliche Kosten durch Arbeitsunf\u00e4higkeit 2022. Verf\u00fcgbar unter. 2023 [cited 2024 Nov 29]. Available from: https:\/\/www.baua.de\/DE\/Themen\/Monitoring-Evaluation\/Zahlen-Daten-Fakten\/Kosten-der-Arbeitsunfaehigkeit."},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.04.014"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-024-03262-w"},{"key":"e_1_3_5_50_1","unstructured":"Destatis. Germany\u2019s Population by 2050: results of the 11th coordinated population projection. Verf\u00fcgbar unter. 2006 [cited 2024 Nov 29]. Available from: https:\/\/www.destatis.de\/EN\/Themes\/Society-Environment\/Population\/Population-Projection\/Publications\/Downloads-Population-Projection\/germany-population-2050.pdf?__blob=publicationFile."},{"key":"e_1_3_5_51_1","unstructured":"WHO. The changing face of pandemic risk: how we need to adapt protect and connect. Verf\u00fcgbar unter. 2025 [cited 2025 Apr 29]. Available from: https:\/\/www.who.int\/news\/item\/05-02-2025-the-changing-face-of-pandemic-risk\u2013how-we-need-to-adapt\u2013protect-and-connect."},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40258-023-00815-7"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40258-023-00803-x"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2022.100602"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2023.09.025"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2024.02.001"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.3310\/NAFW3527"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac637"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.p1041"},{"key":"e_1_3_5_60_1","unstructured":"Campbell JD Whittington MD Rind DM et\u00a0al. 2020. Alternative pricing models for remdesivir and other potential treatments for COVID-19: updated report. Verf\u00fcgbar unter. [cited 2024 Nov 29]. Available from: https:\/\/icer.org\/wp-content\/uploads\/2020\/11\/ICER-COVID_Updated_Report_11102020.pdf."}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2025.2536974","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T10:48:46Z","timestamp":1766400526000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2025.2536974"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,31]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12,31]]}},"alternative-id":["10.1080\/13696998.2025.2536974"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2025.2536974","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,31]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-05-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-17","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}